<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Stovall, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2229954920"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is marked by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and nearly always includes episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Despite clinical differences between manic and hypomanic episodes, they are treated with the same medications [<a href="#rid2">2-9</a>].</p><p>This topic reviews the general principles of administering pharmacotherapy for acute mania and hypomania in adults. Choosing a specific pharmacotherapy regimen for acute mania and hypomania is discussed separately, as is choosing a regimen for bipolar depression and maintenance treatment. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a> and  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="headingAnchor" id="H778607247"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p>Despite clinical differences among manic and hypomanic episodes (eg, hypomania is less severe than mania), they are treated with the same medications [<a href="#rid2">2-9</a>].</p><p class="headingAnchor" id="H3303011715"><span class="h1">GENERAL TREATMENT PRINCIPLES</span></p><p class="headingAnchor" id="H561372134"><span class="h2">Nature of the evidence</span><span class="headingEndMark"> — </span>Evidence for the efficacy of treating mood elevated syndromes with medications is primarily based upon randomized trials with bipolar I manic patients; most trials included some patients with mixed features (ie, mania accompanied by symptoms of depression) [<a href="#rid10">10,11</a>]. Even though bipolar II disorder is more prevalent than bipolar I disorder, relatively little research has focused specifically on treating hypomania [<a href="#rid12">12,13</a>]. Many randomized trials either exclude patients with bipolar II disorder or combine them with bipolar I patients in the analyses.</p><p class="headingAnchor" id="H3976079192"><span class="h2">Similar approach for mania and hypomania</span><span class="headingEndMark"> — </span>Despite clinical differences between manic and hypomanic episodes (eg, hypomania is less severe than mania), they are treated with the same medications [<a href="#rid2">2-9</a>].</p><p class="headingAnchor" id="H3089332532"><span class="h2">Assessment and monitoring</span><span class="headingEndMark"> — </span>Treatment of mood elevated syndromes (ie, manic and hypomanic episodes) begins with an initial psychiatric history and mental status examination that emphasizes symptoms of the mood episode, particularly risk of suicide, aggressiveness, and violence to others, as well as signs of catatonia and psychosis [<a href="#rid5">5,8,9,14</a>]. Clinicians should also assess patients for comorbid disorders (eg, substance use disorders) that require treatment. The evaluation includes a general medical history, physical examination, and focused laboratory studies to establish whether the mood syndrome is due to the direct physiologic effects of a general medical condition, and to rule out any contraindications to treatment (eg, renal impairment and use of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, or hepatic disease and use of <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>). Additional information about the assessment for bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p>Patients who suffer mania or hypomania during maintenance pharmacotherapy should be assessed for adherence to treatment [<a href="#rid9">9</a>]. Managing poor adherence is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy"</a>.)</p><p>In addition, clinicians should assess patients for use of substances that may cause or exacerbate a mood elevated syndrome. (See <a class="local">'Destabilizing drugs'</a> below.)</p><p>Once treatment commences, clinicians can monitor outcomes by administering a standardized rating scale such as the Young Mania Rating Scale [<a href="#rid15">15</a>] or the Mania Rating Scale derived from the Schedule for Affective Disorders and Schizophrenia, Change Version [<a href="#rid16">16</a>]. Although these 11-item instruments are routinely used for systematically measuring outcome in research settings, this is not standard clinical practice. In addition, these scales were developed in 1978 and thus may not fully reflect our current nosology, which views increased goal-directed activity or energy as a core symptom of mania [<a href="#rid1">1,17,18</a>].</p><p class="headingAnchor" id="H1712222315"><span class="h2">Level of care</span><span class="headingEndMark"> — </span>The treatment setting for manic or hypomanic patients depends upon the severity of symptoms, comorbid psychopathology (eg, substance use disorder), level of psychosocial functioning, and available support:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inpatient</strong> – Hospitalization may be required for managing the patient’s safety and symptoms such as suicidal ideation with a specific plan and intent, delusions or hallucinations, catatonia, and poor judgment that poses an imminent risk to the patient and others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial hospital</strong> – Moderately ill patients can often be treated in a partial hospital (day) program, including patients with suicidality that does not pose an imminent risk (eg, patients with fleeting thoughts of killing oneself, vague or nonexistent plans, and no intent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient</strong> – Outpatient care may be suitable for less acutely ill patients (eg, patients with thoughts that family members would be better off if the patient was dead, with no plan or intent to commit suicide).</p><p></p><p>For outpatient treatment of bipolar disorder, specialized mood disorder clinics may be preferable to general (standard) psychiatric clinics early in the course of illness. An open-label, two-year, randomized trial compared a mood disorder clinic with standard care in 158 bipolar patients who were discharged from their first, second, or third inpatient admission [<a href="#rid19">19</a>]. The mood disorder clinic was staffed by a cross-disciplinary team who administered pharmacotherapy and group psychoeducation; standard care consisted of pharmacotherapy provided at a local community health center or at a psychiatrist’s office. Readmission to the hospital occurred in fewer patients who received specialized care than standard care (36 versus 55 percent). In addition, the median duration of the readmission was nearly two times shorter for patients who had received specialized care rather than standard care (12 versus 22 days).</p><p>The frequency of assessment generally ranges from daily to monthly, depending upon the severity of persistent symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves may require constant observation.</p><p>Among patients who are hospitalized for mania, outpatient follow-up should occur within at least 30 days of discharge. A retrospective study of administrative health care data found that among nearly 11,000 patients who were hospitalized for mania and then discharged, readmission was 30 percent less likely in patients who received outpatient care within 30 days, compared with patients who did not (attributable odds ratio 0.7, 95% CI 0.6-0.9) [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1365484325"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The initial goal of treating acute mania and hypomania is rapid response, which is defined as stabilization of the patient’s safety and substantial improvement in the number, intensity, and frequency of mood (and psychotic) symptoms [<a href="#rid9">9</a>]. Many randomized trials of antimanic medications determine efficacy on the basis of response that is operationalized as a reduction of baseline symptoms ≥50 percent [<a href="#rid21">21,22</a>]. These studies assess outcomes with a standardized rating scale. (See <a class="local">'Assessment and monitoring'</a> above.)</p><p>The ultimate goal of treating acute mania and hypomania is remission, which is defined as resolution of the mood symptoms or improvement to the point that only one or two symptoms of mild intensity persist [<a href="#rid9">9,22</a>]. If patients present with psychotic features (delusions or hallucinations), resolution of the psychosis is required for remission. Patients with subsyndromal symptoms of mania are at increased risk of relapse [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H969171430"><span class="h2">Drug classes</span><span class="headingEndMark"> — </span>Based upon randomized trials, drug classes commonly used to treat acute mania or hypomania include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a></p><p class="bulletIndent1"><span class="glyph">●</span>Anticonvulsants</p><p class="bulletIndent1"><span class="glyph">●</span>Antipsychotics</p><p class="bulletIndent1"><span class="glyph">●</span>Benzodiazepines</p><p></p><p>The mainstays of treatment are <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, anticonvulsants, and antipsychotics used in combination pharmacotherapy (eg, lithium plus an antipsychotic) or as monotherapy, depending upon the severity of symptoms. Benzodiazepines are primarily used as adjunctive treatment for insomnia, agitation, or anxiety. The general treatment of insomnia, agitation, and anxiety are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">"Overview of the treatment of insomnia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a> and  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a>.)</p><p class="headingAnchor" id="H505326155"><span class="h2">Duration of an adequate trial</span><span class="headingEndMark"> — </span>Although it is not established how long clinicians should wait to assess the benefit of a medication regimen, it is reasonable to allow up to two weeks for a treatment trial [<a href="#rid2">2,5,8</a>]. However, clinical urgency when treating hospitalized patients may necessitate shorter trials lasting one week or even less.</p><p>Most randomized trials last three weeks, and the superior efficacy of active drugs compared with placebo generally begins to manifest within one week [<a href="#rid5">5,21,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial that compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> with <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> in patients with pure mania or mania with mixed features, improvement at week 1 was evaluated as a predictor of either remission or response (reduction of baseline symptoms ≥50 percent) at week 3 [<a href="#rid24">24</a>]. Among 234 patients with improvement ≥25 percent at week 1, 52 percent remitted and 71 percent responded at week 3. Conversely, of the 40 patients with &lt;25 percent improvement at week 1, 5 percent remitted and 25 percent responded at week 3.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 12 randomized trials compared <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> plus an antipsychotic with lithium, valproate, or carbamazepine monotherapy in a total of 3164 patients with acute manic or mixed episodes [<a href="#rid23">23</a>]. At week 3, improvement of mania was greater with combination therapy than monotherapy, and the advantage of combination therapy first manifested at week 1.</p><p></p><p class="headingAnchor" id="H282851753"><span class="h2">Predictors of response</span><span class="headingEndMark"> — </span>Among patients with mania, clinical factors that consistently predict a good response to pharmacotherapy have not been identified. As an example, several studies suggest that mixed features are associated with a poorer response [<a href="#rid12">12,25-28</a>], whereas other studies indicate that response to medications is comparable for patients with pure mania and mania with mixed features [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H1462995858"><span class="h2">Relapse during maintenance phase</span><span class="headingEndMark"> — </span>Patients who suffer mania or hypomania during maintenance pharmacotherapy are initially treated by optimizing existing medication doses [<a href="#rid6">6,7,9</a>]. This includes ensuring serum concentrations are in the therapeutic range for medications such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, as well as increasing the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene. For medications that do not have an established therapeutic serum concentration, such as second-generation antipsychotics, the dose can be increased within the target dose range.</p><p>Patients who discontinue successful maintenance treatment and then suffer a relapse are often restarted on the same medication. Although concerns have been raised that the same medication is less effective after treatment is interrupted, a meta-analysis of three prospective observational studies (n = 212 patients with bipolar disorder) suggested that this was not the case.</p><p class="headingAnchor" id="H3749508263"><span class="h2">Destabilizing drugs</span><span class="headingEndMark"> — </span>Patients should reduce or eliminate their use of substances that may cause or exacerbate a mood elevated syndrome, such as alcohol, caffeine, and nicotine [<a href="#rid9">9</a>]. In addition, antidepressants should be abruptly discontinued [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H488454386"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>Although some primary care clinicians have the requisite training and experience to manage bipolar disorder, many patients are referred to psychiatrists and other mental health clinicians if these specialists are available. Common indications for referral include:</p><p class="bulletIndent1"><span class="glyph">●</span>Suicidal ideation and behavior</p><p class="bulletIndent1"><span class="glyph">●</span>Psychotic features (eg, auditory hallucinations commanding patients to kill themselves)</p><p class="bulletIndent1"><span class="glyph">●</span>Fluctuating symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Impulsive and dangerous behavior</p><p class="bulletIndent1"><span class="glyph">●</span>Functional impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid psychopathology (eg, anxiety disorders and substance use disorders)</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple (eg, two to four) failed medication trials</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of adjunctive psychotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence of mood episodes</p><p></p><p>Primary care clinicians who refer patients to specialists are encouraged to remain involved in management. General internists and other clinicians can help educate patients and families about pharmacotherapy and reinforce the need for adherence, and typically collaborate in evaluating patients prior to treatment and monitoring vital signs, weight, height, and waist size during treatment.</p><p class="headingAnchor" id="H2802636877"><span class="h1">CHOOSING TREATMENT</span><span class="headingEndMark"> — </span>Choosing a specific treatment regimen for acute mania and hypomania in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="headingAnchor" id="H3921507674"><span class="h1">TREATING SPECIFIC SUBGROUPS</span></p><p class="headingAnchor" id="H2504543673"><span class="h2">Rapid cycling patients</span><span class="headingEndMark"> — </span>Pharmacotherapy for mania and hypomania that occur in the context of rapid cycling is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania"</a>.)</p><p class="headingAnchor" id="H1369025421"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>Pharmacotherapy for antenatal mania and hypomania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">"Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania"</a>.)</p><p class="headingAnchor" id="H2561817651"><span class="h2">Postpartum patients</span><span class="headingEndMark"> — </span>Pharmacotherapy for postnatal mania and hypomania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment"</a>.)</p><p class="headingAnchor" id="H2148772210"><span class="h2">Geriatric patients</span><span class="headingEndMark"> — </span>Pharmacotherapy for late-life mania and hypomania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a>.)</p><p class="headingAnchor" id="H449746610"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>Pharmacotherapy for pediatric mania and hypomania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment"</a>.)</p><p class="headingAnchor" id="H2789302316"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H1852839699"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment in a booklet entitled "Bipolar Disorder," which is available online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=119372" target="_blank">website</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002) and An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison PhD (published by Random House, 1995).</p><p>The Depression and Bipolar Support Alliance (available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=119372" target="_blank">website</a> or 800-826-3632) is a national organization whose mission is to educate patients and family members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by members and has local chapters.</p><p>The National Alliance on Mental Illness (available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=119372" target="_blank">website</a> or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class="headingAnchor" id="H3759925638"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>). (See <a class="local">'Definition of bipolar disorder'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Choosing a medication regimen for patients with acute bipolar mania and hypomania depends in part upon the severity of the syndrome. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite clinical differences between manic and hypomanic episodes, they are treated with the same medications. (See <a class="local">'Similar approach for mania and hypomania'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial goal of treating acute mania and hypomania is rapid response, which is defined as stabilization of the patient’s safety and substantial improvement in symptoms. The ultimate goal is remission. (See <a class="local">'Goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of mood elevated syndromes begins with an initial psychiatric history and mental status examination, as well as a general medical history, physical examination, and focused laboratory studies. Once treatment commences, clinicians can monitor outcomes by administering a standardized rating scale, but this is not standard clinical practice. (See <a class="local">'Assessment and monitoring'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although it is not established how long clinicians should wait to assess the benefit of a medication regimen, it is reasonable to allow up to two weeks for a treatment trial. However, clinical urgency when treating hospitalized patients may necessitate shorter trials lasting one week or even less.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with mania, clinical factors that consistently predict a good response to pharmacotherapy have not been identified. (See <a class="local">'Predictors of response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mania or hypomania that occurs during maintenance pharmacotherapy is initially treated by optimizing existing medication doses. Patients who discontinue successful maintenance treatment and then suffer a relapse are often restarted on the same medication. (See <a class="local">'Relapse during maintenance phase'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should reduce or eliminate their use of substances that may cause or exacerbate a mood elevated syndrome. (See <a class="local">'Destabilizing drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although some primary care clinicians can manage bipolar disorder, many patients are referred to psychiatrists and other mental health clinicians if these specialists are available. (See <a class="local">'Indications for referral'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.</a></li><li><a class="nounderline abstract_t">Benazzi F. Bipolar II disorder : epidemiology, diagnosis and management. CNS Drugs 2007; 21:727.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord 2012; 14 Suppl 2:22.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li class="breakAll">NICE National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. September 2014. http://www.nice.org.uk/guidance/CG185 (Accessed on November 18, 2014).</li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.</a></li><li><a class="nounderline abstract_t">Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.</a></li><li><a class="nounderline abstract_t">McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149:1633.</a></li><li><a class="nounderline abstract_t">Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006; 20:29.</a></li><li><a class="nounderline abstract_t">Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.</a></li><li><a class="nounderline abstract_t">Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429.</a></li><li><a class="nounderline abstract_t">Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837.</a></li><li><a class="nounderline abstract_t">Scott J, Murray G. Are rating scales for bipolar disorders fit for purpose? Br J Psychiatry 2018; 213:627.</a></li><li class="breakAll">World Health Organization. International Classification of Diseases-11th Revision (ICD-11). http://www.who.int/classifications/icd/en/ (Accessed on October 24, 2018).</li><li><a class="nounderline abstract_t">Kessing LV, Hansen HV, Hvenegaard A, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry 2013; 202:212.</a></li><li><a class="nounderline abstract_t">Marcus SC, Chuang CC, Ng-Mak DS, Olfson M. Outpatient Follow-Up Care and Risk of Hospital Readmission in Schizophrenia and Bipolar Disorder. Psychiatr Serv 2017; 68:1239.</a></li><li><a class="nounderline abstract_t">Yildiz A, Nikodem M, Vieta E, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 2015; 45:299.</a></li><li class="breakAll">Keck Jr. PE, McElroy SL. Treatment of bipolar disorder. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1177.</li><li><a class="nounderline abstract_t">Ogawa Y, Tajika A, Takeshima N, et al. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014; 28:989.</a></li><li><a class="nounderline abstract_t">Kemp DE, Johnson E, Wang WV, et al. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry 2011; 72:1236.</a></li><li><a class="nounderline abstract_t">Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry 2010; 67:339.</a></li><li><a class="nounderline abstract_t">Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry 2013; 170:31.</a></li><li><a class="nounderline abstract_t">Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54:37.</a></li><li><a class="nounderline abstract_t">Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271:918.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003; 23:370.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Tohen M, Berk M, et al. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord 2013; 150:378.</a></li></ol></div><div id="topicVersionRevision">Topic 119372 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19347775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696573" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bipolar II disorder : epidemiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510034" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy of antimanic treatments in mixed states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845269" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1359799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396522" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Polytherapy in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/728692" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A rating scale for mania: reliability, validity and sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/678037" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A diagnostic interview: the schedule for affective disorders and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339112" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Are rating scales for bipolar disorders fit for purpose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339112" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Are rating scales for bipolar disorders fit for purpose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349295" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669289" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outpatient Follow-Up Care and Risk of Hospital Readmission in Schizophrenia and Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036226" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036226" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25160685" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21457677" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368510" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Longitudinal course of bipolar I disorder: duration of mood episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223893" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006398" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Depression during mania. Treatment response to lithium or divalproex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120960" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920413" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Olanzapine versus placebo in acute mania: treatment responses in subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23712026" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
